TABLE 1.
Baseline Characteristics of Venous Thromboembolism Cases and Controls
| Baseline Characteristic | Cases (n=1340) |
Controls (n=1538) |
|---|---|---|
| Statin lipid lowering therapy alone, n (%) | 67 (5.0) | 101 (6.6) |
| Lovastatin, n (%) | 25 (37.3) | 35 (34.7) |
| Simvastatin, n (%) | 21 (31.3) | 33 (32.7) |
| Atorvastatin, n (%) | 11 (16.4) | 17 (16.8) |
| Pravasatatin, n (%) | 7 (10.4) | 12 (11.9) |
| Fluvastatin, n (%) | 4 (6.0) | 5 (5.0) |
| Non-statin lipid lowering therapy alone, n (%) | 25 (1.9) | 40 (2.6) |
| Niacin, n (%) | 11 (44.0) | 19 (47.5) |
| Gemfibrozil, n (%) | 10 (40.0) | 16 (40.0) |
| Cholestyramine, n (%) | 4 (16.0) | 7 (17.5) |
| Cholestipol, n (%) | 1 (4.0) | 0 (0.0) |
| Both statin and non-statin therapy, n (%) | 7 (0.5) | 10 (0.7) |
| Age, mean ± SD | 65.0 (19.0) | 64.6 (18.8) |
| Female, n (%) | 744 (55.5) | 850 (55.3) |
| Body mass index (BMI, kg/m2), mean ± SD | 27.9 ± 7.0 | 26.7 ± 5.3 |
| Trauma / fracture, n (%) | 171 (12.8) | 40 (2.6) |
| Hospitalized +/− surgery†, n (%) | 613 (45.7) | 138 (9.0) |
| Active cancer, n (%) | 333 (24.9) | 49 (3.2) |
| Neurological disease n (%) | 93 (6.9) | 13 (0.8) |
| Pacemaker/vascular catheterization n (%) | 240 (17.9) | 51 (3.3) |
| Varicose veins, n (%) | 365 (27.2) | 354 (23.0) |
| Nursing home confinement§ n (%) | 170 (12.7) | 104 (6.8) |
| Prior Superficial Thrombosis, n (%) | 203 (15.1) | 84 (5.5) |
| Oral Contraceptives (Females Only), n (%) | 61 (8.2) | 41 (4.8) |
| Females, Age 18–45, n (%) | 54 (43.2) | 38 (26.8) |
| Females, Age 46+, n (%) | 5 (0.8) | 2 (0.3) |
| Pregnancy/Postpartum (Females Only), n (%) | 25 (3.4) | 10 (1.2) |
| Females, Age 18–45, n (%) | 25 (20.0) | 10 (7.0) |
| Estrogen/Progesterone/Oral Contraceptives*, n (%) | 227 (16.9) | 176 (11.4) |
| Females, Age 18–45, n (%) | 65 (52.0) | 46 (32.4) |
| Females, Age 46+, n (%) | 138 (22.7) | 126 (18.2) |
| Pulmonary Hypertension, n (%) | 57 (4.3) | 23 (1.5) |
| Diabetes, n (%) | 168 (12.5) | 142 (9.2) |
| CHF, n (%) | 243 (18.1) | 152 (9.9) |
| PFO, n (%) | 24 (1.8) | 22 (1.4) |
| Angina/MI, n (%) | 338 (25.2) | 289 (18.8) |
| Congenital Heart Disease, n (%) | 9 (0.7) | 1 (0.1) |
| Cardiomyopathy, n (%) | 29 (2.2) | 24 (1.6) |
| Valvular Heart Disease, n (%) | 165 (12.3) | 137 (8.9) |
| Stroke, n (%) | 239 (17.8) | 184 (12.0) |
| Peripheral Vascular Disease, n (%) | 166 (12.4) | 144 (9.4) |
| Ever Smoker, n (%) | 699 (52.2) | 759 (49.3) |
| Current Smoker, n (%) | 177 (13.2) | 209 (13.6) |
| Former Smoker, n (%) | 522 (39.0) | 550 (35.8) |
| Never Smoker, n (%) | 641 (47.8) | 779 (50.7) |
| Warfarin, n (%) | 44 (3.3) | 43 (2.8) |
| Heparin, n (%) | 53 (4.0) | 6 (0.4) |
†
In hospital or within 92 days of previous hospitalization compared to no hospitalization in the past 92 days. Includes patients hospitalized with surgery or for acute medical illness.
*
Nineteen cases and two controls where males are on estrogen/progesterone.
§
Two cases are missing nursing home confinement